Central Queensland Public Health Unit

Summarised AIH Adult Pneumococcal Recommendations

Risk of invasive disease	Indigenous status	Age	Prevenar 13® is NOT funded	Pneumovax 23® is FUNDED for <i>ALL</i> of the following listed below
Normal (healthy)	Non-Indigenous	<u>></u> 65yrs	Not recommended	Single dose only
non-smoker	Indigenous	<u>></u> 50yrs	Not recommended	Two doses: 2 nd dose is given 5 years after 1 st dose
Increased risk (Category B)	Non-Indigenous	18-64yrs <u>></u> 65yrs	Not recommended Not recommended	Three doses: 2 nd dose is given 5-10 years after 1 st dose. 3 rd dose is given at 65years or 5 years after 2nd dose, whichever is later Two doses: 2 nd dose is given 5 years after 1 st dose
	Indigenous	18-49yrs ≥50yrs	Not recommended Not recommended	Three doses: 2 nd dose is given 5-10 years after 1 st dose. 3 rd dose is given at 50 years or 5 years after 2 nd dose, whichever is later Two doses: 2 nd dose is given 5 years after 1 st dose
Highest risk (Category A)	Non-Indigenous	18-64yrs <u>></u> 65yrs	NOT FUNDED Single dose given at diagnosis #	Three doses: 1st dose is given 2 months after Prevenar 13, 2nd dose is given 5 years after 1st dose. 3rd dose is given at 65 years or 5 years after 2nd dose, whichever is later Three doses: 1st dose is given 2 months after Prevenar 13, 2nd dose is given 5 years after 1st dose. 3rd dose is given 5 years after 2nd dose.
Refer to # Note for <u>all</u>	# NOTE: for Cat	tegory A, if F	Pneumovax 23 has alı	ready been given, wait 12mths then give Prevenar 13.
Category A groups Then continue with subsequent Pneumovax 23 dose/s as recommended, noting correct intervals				
	Indigenous	18-49yrs	^	Three doses: 1st dose is given 2 months after Prevenar
Exception ** HSCT - refer to specific recommendations in AIH, under 'Special Groups',		<u>></u> 50yrs	NOT FUNDED Single dose given at diagnosis #	13, 2nd dose is given 5 years after 1st dose. 3rd dose is given at 50 years or 5 years after 2nd dose, whichever is later
then 'Immunocompromised'				Three doses: 1st dose is given 2 months after Prevenar 13, 2nd dose is given 5 years after 1st dose. 3rd dose is given at 65yrs or 5 years after 2nd dose 2, whichever is later

Counting doses: Any dose of Pneumovax 23 given after 15 years of age should be counted as an adult dose. The minimum interval between any 2 doses of 23vPPV should be 5 years, and no more than 3 lifetime adult doses of 23vPPV are recommended. For more info, call CQPHU 07 4920 6989

Category A: Conditions associated with the highest increased risk of IPD	Category B: Conditions associated with increased risk of IPD
Functional or anatomical asplenia, including: sickle cell disease or other haemoglobinopathies; congenital or acquired asplenia (e.g. splenectomy), splenic dysfunction Immunocompromising conditions, including: (refer to on-line AIH for further details) - Congenital or acquired immune deficiency - Immunosuppressive therapy - Haematological and other malignancies - Solid organ transplant - **Haematopoietic stem cell transplant (HSCT) (refer to AIH table for specific recommendations) - HIV (including AIDS) - Chronic renal failure, or relapsing or persistent nephrotic syndrome - Proven or presumptive cerebrospinal fluid leak - Cochlear implants	Chronic cardiac disease: particularly cyanotic heart disease or cardiac failure in children; excluding hypertension only (in adults) Chronic lung disease: chronic lung disease in preterm infants; cystic fibrosis; severe asthma in adults (requiring frequent medical consultations and use of multiple medications) Diabetes Down Syndrome Alcoholism Chronic liver disease Preterm birth at <28weeks gestation Tobacco smoking

Refer to the on-line Australian Immunisation Handbook [AIH] for detailed information on 'Recommendations' and 'Risk' conditions for IPD

- Intracranial shunts